(PharmaNewsWire.Com, July 20, 2017 ) The report entitled "The US Onychomycosis Market (2017 Edition) " provides analysis of the US onychomycosis market with detailed analysis of market size and growth market share and economic impact of the industry. The analysis includes the market by value by volume and by segments. The report also includes the detailed analysis of the segments of the onychomycosis market comprising of market by value by volume and by average prices.
Valeant Pharmaceuticals Pfizer Inc. Novartis AG and Johnson & Johnson are some of the key players operating in the US onychomycosis market whose company profiling has been done in the report. In this segment of the report business overview financial overview and business strategies of the companies are provided.
Company Coverage Valeant Pahrmaceuticals Pfizer Inc. Johnson and Johnson Novartis AG
Executive Summary Onychomycosis is a condition of fungal nail infection. Onychomycosis begins in the nail bed and progresses to the nail plate causing the nail to become discolored deformed and even separated from the nail bed. Onychomycosis has a significant chance of reoccurrence. Of all the nail abnormalities in the world around 50% are the case of onychomycosis. In most of the cases it occurs in the toenails. Onychomycosis is not a life threatening disease but may persist or worsen if not treated. Symptoms of onychomycosis are changes in appearance of the nail interference with standing walking and exercising pain discomfort etc. The causative pathogens of onychomycosis include dermatophytes (most common) Candida and nondermatophytic molds.
There are five types of Onychomycosis Distal Subungual Onychomycosis White superficial onychomycosis Proximal subungual onychomycosis Endonyx onychomycosis and Candidal onychomycosis. Two types of treatments are available of onychomycosis Oral Treatment and Topical Treatment. Oral treatment includes Terbinafine Itraconazole etc. and topical treatment includes Kerydin Jublia etc. Nonpharmacologic approaches are also there which includes the following Laser treatment Photodynamic therapy etc.
The US onychomycosis market (prescription drugs) has increased with a healthy growth rate over the years and is expected to increase further during the forecasted period. The US onychomycosis market is supported by various growth drivers such as rising per capita healthcare expenditure increasing diabetic patients ageing population introduction of new drugs etc. Yet the market faces certain challenges such as reimbursements low awareness side effects etc.
Company Profiling 5.1 Valeant Pharmaceuticals 5.1.1 Business Overview 5.1.2 Financial Overview 5.1.3 Business Strategy 5.2 Pfizer 5.2.1 Business Overview 5.2.2 Financial Overview 5.2.3 Business Strategy 5.3 Johnson & Johnson 5.3.1 Business Overview 5.3.2 Financial Overview 5.3.3 Business Strategy 5.4 Novartis AG 5.4.1 Business Overview 5.4.2 Financial Overview 5.4.3 Business Strategy
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
